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Objectives: Medicine shortages are a global phenomenon. A growing number of 
reports indicate the problem is increasingly affecting the European pharmaceutical 
market. The present study aims to investigate the characteristics, determinants, 
legal aspects and management of medicine shortages in Belgium, France and from 
the perspective of the European Union. MethOds: A review of scientific and grey 
literature was performed. The legal framework on European and national level 
was reviewed. Primary qualitative data was collected through 22 semi-structured 
interviews with key representatives of health care systems’ stakeholders on the 
national and European level. Results: France reported three times more shortages 
than Belgium. However, the main therapy area, the major cause and the dynamics 
of medicine shortages were analogous between the two countries. Determinants 
of medicine shortages were categorised in manufacturing problems, distribution 
and supply issues, and economic-related challenges. Manufacturing problems 
were most frequently reported as the primary cause of medicine shortages. Laws 
and regulations related to medicine shortages are more extensive in France than 
Belgium. Several preventive and responsive measures were identified to address 
such shortages. cOnclusiOns: Although medicine shortages are country-specific, 
the underlying mechanisms of medicine shortages appear to be similar in Belgium 
and France. Economic aspects seem to play a central role in the phenomenon of 
medicine shortages, as it influences stakeholders’ business decisions. The impact 
of the legal framework around medicines on the occurrence of medicine shortages 
may be limited. Collaboration, communication and coordination are key to any 
effective approach to address medicine shortages.
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Objectives: Firstly, to review whether medicines that have received expedited 
regulatory approval in the European Union (EU) subsequently received positive 
recommendations from selected Health Technology Assessment (HTA) agen-
cies in the EU. A second objective was to understand the reasons for negative 
appraisals of these medicines by EU HTA agencies. MethOds: Medicines that 
have received Conditional Marketing Authorisation (CMA) by the European 
Medicines Agency (EMA) were identified from the EMA website. Websites of HTA 
agencies in the United Kingdom (NICE, SMC); Ireland (NCPE), France (HAS) and 
Germany (IQWiG) were searched to ascertain whether these medicines had been 
appraised. Appraisal reports were reviewed. For medicines with at least one nega-
tive appraisal, reason (s) for the negative appraisal were identified. Results: 
13 medicines have received CMA in the EU. 10 of these medicines have received 
a negative appraisal by at least one HTA agency (either ‘not recommended’ or 
deemed to offer ‘no additional benefit’ over existing treatment). Of the 10 medi-
cines with at least one negative appraisal, 8 are oncology medicines. The most 
common reason for a negative appraisal (relevant to 9 of the 10 medicines) was 
insufficient or uncertain clinical effectiveness. Uncertain cost-effectiveness in 
relation to the proposed treatment cost was mentioned as a source of uncertainty 
for 5 of the 10 medicines. cOnclusiOns: Despite receiving expedited regulatory 
approval, patient access to innovative medicines in the EU may be delayed due 
to negative appraisal of these medicines by HTA agencies (most often due to a 
relative lack of data on clinical effectiveness). Such delays obviate the intention 
of expedited regulatory review of medicines.
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Objectives: To provide a comprehensive description of the current Drug 
Reimbursement Systems in Algeria and to compare it to two archetypes drug reim-
bursement systems in France and UK and to a system in a middle income country: 
Turkey where the HTA has been recently implemented. MethOds: We collected and 
reviewed relevant information to describe the health care and drug reimbursement 
systems in these countries; we reviewed the legal framework and procedure docu-
ments. For Algeria, in addition to the data and information collected, we conducted 
informal interviews supplemented by a survey among key stakeholders. Results: 
Compared to the UK, no similarities were found. This is probably due to the cultural 
differences and the lack of expertise in the use of cost-effectiveness approaches. 
Compared to the France, we didn’t find similarities, except the final decision which 
is taken at the Ministry level. This is due to the administrative nature and the lack 
of transparency of the assessment in Algeria especially where the methods as well 
as the results of the assessment are not explicitly expressed. Compared to Turkey, 
we found some similarities in terms of process, but not in terms of methods as this 
country is now more familiar with the HTA approach. cOnclusiOns: Our study 
shows that the implementation of HTA differs according to cultural and financial 
factors and to expertise capacity in data collection, analysis and use in the decision 
making process. The use of HTA in the drug evaluation and reimbursement system 
in Algeria is underestimated and underdeveloped. That’s why before adopting HTA 
approaches in the pharmaceutical sector, the Algerian authorities should consider 
these factors and improve the data quality and decision process transparency. This 
is becoming vital as cost of drugs is increasing and the fiscal space will be more 
constrained in the near future.
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the reduction of pharmaceutical expenditure was one of the main targets for fiscal 
adjustment. The purpose of this study was to assess the usage of generic medicines 
in Greece, as a key driver for savings from the pharmaceutical market, and compare 
it with that of other major European countries. MethOds: IMS data from several 
European countries was collected in terms of the overall retail pharmaceutical mar-
ket and the consumption of generic medicines in each of them. Focus was placed 
on the top-10 genericized molecules for Greece including alendronic acid, atorv-
astatin, carvedilol, clarithromycin, clopidogrel, donepezil, fluconazole, olanzapine, 
omeprazole and simvastatin. To ensure an “apples-to-apples” comparison across 
countries, the study focused on the retail market only (excluding hospitals) given 
that, in Greece, there is no publicly-available data for pharmaceutical consump-
tion within the hospital setting. Results: The analysis indicated that, in Greece, 
the penetration of generic medicines within the top-10 genericized molecules was 
65% in terms of volume, with off-patent medicines holding the remaining 35%. 
According to IMS data, Greece had a lower penetration of 21 percentage points 
(-24%) versus the weighted European average and -8.2 percentage points (-11%) 
versus the cluster of Southern European countries plus Ireland for calendar year 
2013. cOnclusiOns: Generic penetration within the 10 largest genericized mol-
ecules, in Greek retail-pharmacy setting, is significantly lower versus the weighted 
average of major European countries but also compared to that of countries in 
similar economic situation with Greece.
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Objectives: The practice of generic medicines prescribing, dispensing and 
substitution in developing countries has been controversial among health care 
professionals, particularly due to issues on quality, safety and efficacy. These con-
troversies are as a result of inter-country differences in policies and laws as well 
as individualized knowledge and attitudes of pharmacists pertaining to generic 
medicines. This study primarily aims to assess the knowledge, attitudes, and prac-
tices of community pharmacists in Qatar towards generic medicines. MethOds: A 
cross-sectional study using a pretested paper-based survey was conducted among 
a random sample of community pharmacists in Qatar. The data were analyzed 
using IBM–SPSS® version 20. Both descriptive and inferential statistical analyses 
were applied. Results: A total of 160 surveys were distributed to community phar-
macists of which 118 were returned (response rate, 74%). The mean total score of 
generic medicines knowledge among the pharmacists was 6.8 ± 1.6 (maximum 
possible score was 10). Years of practice as well as place of obtaining academic 
degree did not influence knowledge score. Approximately 72% of the pharmacists 
supported generic substitution for brand name drugs in all cases where a generic 
medicine is available and the majority (93%) agreed that pharmacists should be 
given generic substitution right. Nearly 61% of the pharmacists considered lack 
of proven bioequivalence to original brands as an important barrier for selecting 
generic medicines and 55% rated “lack of policy for directing the practice of generic 
medicine” as an important barrier. cOnclusiOns: In order to enhance the quality 
use of and to promote the practice of generic medicines in Qatar, an educational 
program should be implemented. A national generic medicine policy and guidelines 
are warranted in the State of Qatar.
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Objectives: Encouraging generic drug use has reduced health care costs for payers 
and consumers, but the rate of branded medications therapeutically interchange-
able to generic is not equal across medications disease states. The extent to which 
different systems of care are able to substitute towards generics is not well under-
stood. This study defined and measured the maximum generic rate (MGR) of cur-
rently prescribed drugs and illustrated differences across drugs associated with 
selected underlying diseases. MethOds: Using information in prescription claims 
data, drugs were classified into “potentially generic substitutable” or not based on 
clinical consensus regarding the following algorithm: 1. They did not having have 
a narrow therapeutic index (NTI) as defined by the Food and Drug Administration 
(FDA); 2. Did not belong to one of six protected classes of drugs in Medicare D; 3. They 
were substitutable with a generic medication of the same chemical entity; 4. They 
were therapeutically interchangeable with a generic in the same class which was 
thought clinically to have class effect benefits and minimal risk of harm in switch-
ing. A maximum generic rate (MGR) was defined as the percent of prescriptions 
that could be generic. This rate was examined overall and across drugs known to 
be associated with illustrative diseases including hypertension, diabetes mellitus, 
and obstructive lung disease. Results: The MGR ranged from 100% for drugs used 
in hypertension to 26.7% for drugs used in obstructive lung disease. The overall 
maximum possible generic rate (MGR) was 83.6%. cOnclusiOns: Payers wishing 
to promote generic substitution should incorporate the potential for substitution 
toward clinically appropriate generic medications as part of incentives for generic 
utilization to avoid unintended consequences of using a fixed target rate. A practical 
methodology for determining a MGR is offered here.
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